NBIX Neurocrine Biosciences, Inc.

51.51
0  -1%
Previous Close 51.91
Open 52.25
Price To book 14.32
Market Cap 4.49B
Shares 87,114,000
Volume 1,306,587
Short Ratio 4.36
Av. Daily Volume 1,249,850

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 planned for 2017.
NBI-640756
Essential Tremor
NDA filing planned - license agreement with BIAL announced February 9, 2017.
Opicapone
Parkinson's disease
Phase 2 data due April 2017.
INGREZZA
Tourette syndrome - juvenile
Phase 2 data released January 18, 2017 did not meet primary endpoint.
INGREZZA
Tourette syndrome - adults
Phase 3 initiated by partner Abbvie in January 2016. Data due 4Q 2017.
Elagolix
Uterine Fibroids
First Phase 3 trial met both co-primary endpoints - Jan 2015. Data from second Phase 3 released February 2016 also met endpoints. NDA Filing due 3Q 2017.
Elagolix
Endometriosis
Approved April 11, 2017.
INGREZZA
Tardive dyskinesia

Latest News

  1. Neurocrine Announces INGREZZA™ Long-Term Safety and Efficacy Data to be Presented at the 2017 American Academy of Neurology Annual Meeting
  2. Should You Make a Bet on the Healthcare Stocks?
  3. Neurocrine's Stock Up, FDA Nod for Tardive Dyskinesia Drug
  4. Pharma companies are seeking a new treatment — for the backlash against high drug prices
  5. Company News for April 13, 2017
  6. Blog Coverage Neurocrine Stock Price Rocketed 25% After FDA's First Ever Approval for its Drug for the Treatment of Tardive Dyskinesia
  7. Neurocrine Avoids Suicide Warning In Teva-Rivaling Drug; Stock Pops
  8. Biotech stock Neurocrine surges more than 22% after FDA approves first drug for movement disorder
  9. HP Hits 2-Year High On Upgrade; GrubHub, Neurocrine Touted
  10. NBIX: INGREZZA™ Approved by the FDA
  11. Here's Why Neurocrine (NBIX) Stock is Soaring 24% Today
  12. Neurocine Biosciences gets FDA approval for new drug
  13. Approval For Neurocrine's Ingrezza Was No Surprise, But Lack Of Warning Label A Big Advantage Over Teva
  14. Neurocrine Outperforms Even Bullish Estimates Of Ingrezza Approval Upside
  15. Why Neurocrine Biosciences Stock Is Soaring Higher Today
  16. FDA Approves Neurocrine Biosciences Movement Disorder Therapy
  17. Neurocrine Biosciences Wins Big With FDA Approval
  18. Neurocrine Biosciences Achieves Best Case Scenario With Ingrezza Approval
  19. Biotech Movers: Neurocrine Biosciences Leaps on Drug Approval, Synergy Pharma Issued Three Patents
  20. Neurocrine Biosciences gets FDA's OK for movement disorder drug